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ARTICLE

Iron Metabolism & its Disorders

Increased hepcidin in transferrin-treated
thalassemic mice correlates with increased
liver BMP2 expression and decreased
hepatocyte ERK activation
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ABSTRACT

I

ron overload results in significant morbidity and mortality in
β-thalassemic patients. Insufficient hepcidin is implicated in parenchymal
iron overload in β-thalassemia and approaches to increase hepcidin have
therapeutic potential. We have previously shown that exogenous apo-transferrin markedly ameliorates ineffective erythropoiesis and increases hepcidin
expression in Hbbth1/th1 (thalassemic) mice. We utilize in vivo and in vitro systems to investigate effects of exogenous apo-transferrin on Smad and ERK1/2
signaling, pathways that participate in hepcidin regulation. Our results
demonstrate that apo-transferrin increases hepcidin expression
in vivo despite decreased circulating and parenchymal iron concentrations and
unchanged liver Bmp6 mRNA expression in thalassemic mice. Hepatocytes
from apo-transferrin-treated mice demonstrate decreased ERK1/2 pathway
and increased serum BMP2 concentration and hepatocyte BMP2 expression.
Furthermore, hepatocyte ERK1/2 phosphorylation is enhanced by neutralizing anti-BMP2/4 antibodies and suppressed in vitro in a dose-dependent manner by BMP2, resulting in converse effects on hepcidin expression, and hepatocytes treated with MEK/ERK1/2 inhibitor U0126 in combination with
BMP2 exhibit an additive increase in hepcidin expression. Lastly, bone marrow erythroferrone expression is normalized in apo-transferrin treated thalassemic mice but increased in apo-transferrin injected wild-type mice.
These findings suggest that increased hepcidin expression after exogenous
apo-transferrin is in part independent of erythroferrone and support a model
in which apo-transferrin treatment in thalassemic mice increases BMP2
expression in the liver and other organs, decreases hepatocellular ERK1/2
activation, and increases nuclear Smad to increase hepcidin expression in
hepatocytes.

Introduction
β-thalassemia is characterized by anemia, expanded erythropoiesis, and iron
overload with iron overload principally causing morbidity and mortality in these
patients.1 Although iron overload primarily results from transfused erythrocytes,
transfusion-independent patients also develop iron overload from increased
dietary iron absorption. Iron absorption and iron recycling are regulated by hepcidin, a peptide hormone produced predominantly in the liver. Hepcidin binds ferhaematologica | 2016; 101(3)
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roportin (FPN1), the iron exporter on enterocytes, hepatocytes, and reticuloendothelial macrophages,2 and results in
FPN1 degradation and decreased release of cellular iron,
down-regulating dietary iron absorption, iron release from
stores, and tissue iron recycling. Despite iron overload,
hepcidin is inappropriately low and is thus implicated as
the cause of iron overload in patients with and mouse
models of β-thalassemia.3-7 This lack of appropriate hepcidin response, despite increased parenchymal iron stores,
in β-thalassemia suggests a competing hepcidin-suppressing signal.6-8 In diseases of concurrent iron overload and
ineffective erythropoiesis, hepcidin suppression results
from secretion of bone marrow factors [(e.g. growth differentiation factor 15 (GDF15), twisted gastrulation 1
(TWSG1), GDF11, and erythroferrone (ERFE)].9-12 These
erythroid regulators of hepcidin and their signaling pathways are active areas of investigation targeted for development of novel therapeutics in iron disorders.
We previously demonstrated that exogenous apo-transferrin (apoTf) in Hbbth1/th1 (thalassemic) β-thalassemia intermedia mice markedly ameliorates ineffective erythropoiesis and increases hepcidin expression.13 Mechanisms
of hepcidin regulation involve bone morphogenetic proteins (BMPs). Several BMP signaling molecules up-regulate hepcidin expression in vitro3,14-16 by binding BMP receptors. BMP6 is a principal endogenous BMP regulating hepcidin expression,16,17 and Bmp6 knockout mice exhibit hepcidin suppression with iron overload.17,18 Bmp6 mRNA is
up-regulated in mouse liver following dietary iron overload, suggesting that transcriptional regulation of hepcidin
by iron involves an autocrine or paracrine BMP6 effect.3
However, increased hepcidin in chronically iron-loaded
Bmp6 knockout mice suggests that other pathways stimulate hepcidin expression in response to iron overload.19
Furthermore, when normalized to liver iron content,
Bmp6 expression is not increased in β-thalassemic mice,5
suggesting that hepcidin regulation in conditions of chronic iron overload, such as β-thalassemia, may involve additional molecules. Other BMPs, including BMP2 and 4, also
induce hepcidin regulation in vitro20 and neutralizing
BMP2/4 antibodies suppress hepcidin-responsiveness to
serum and/or holoTf similar to noggin (BMP receptor
blocker) response.21 Lastly, BMP2 injection results in
increased hepcidin expression in vivo,14 but its physiological role in hepcidin regulation has not been fully determined.
Regulation of hepcidin expression in hepatocytes is
dependent on the decapentaplegic (Smad) signaling pathway. BMP receptor binding induces phosphorylation of
intracellular Smad1/5/8, the association of pSmad1/5/8
with Smad4, and the complex translocation to the nucleus
where binding to regulatory elements induces hepcidin
expression. Recent evidence suggests that BMP receptor
signaling is complex and Smad signaling may integrate
with other signaling pathways.22 Specifically, MAP kinase
modulates Smad signaling,23 and, although the details have
not been worked out, may regulate nuclear translocation
or transcriptional activity of pSmad1/5/8.24 Most studies
examining such crosstalk used transformed epithelial cell
lines, with MEK/ERK1/2 pathway reported to enhance25 or
inhibit26 Smad activity depending on cell type- or target
gene-specificity. Several studies provide indirect evidence
that hepatic MEK/ERK1/2 is involved in hepcidin regulation.21,27,28 In particular, MEK/ERK1/2 inhibition did not
suppress hepcidin expression in HepG2 cells28 despite par298

allel increases of MEK/ERK1/2 and Smad signaling in
response to BMP2 and holoTf. Thus, the physiological relevance of the interactions between these signaling pathways in iron homeostasis is still not completely understood.
We postulate that apoTf systemically affects hepatocyte
hepcidin expression via the purported “erythroid regulator”. In addition, we evaluate the role of addition BMPs in
systemic and cellular iron regulation of hepcidin in apoTftreated mice. Lastly, we hypothesize that MEK/ERK1/2
suppression in hepatocytes is involved in stimulating hepcidin expression in apoTf-treated mice. To understand the
mechanisms of hepcidin regulation from these perspectives in apoTf-treated thalassemic mice, we explore ironrelated parameters in circulation, in the liver, and in hepatocytes. Our findings demonstrate that reversal of ineffective erythropoiesis and increased hepcidin in apoTf-treated thalassemic mice correlate with decreased hepatocyte
MEK/ERK1/2 signaling, increased circulating BMP2, and
decreased ERFE expression in erythroid precursors, supporting the hypothesis that exogenous apoTf influences
hepcidin expression both via erythropoiesis- and ironrelated pathways.

Methods
Mice
Hbbth1/th1 (thalassemic) mice were backcrossed onto a C57BL6
background, as previously described.13 Age- and gender-matched
8-10-week old thalassemic and C57BL6 (WT) mice were bred and
housed in the animal facility under AAALAC guidelines. The
experimental protocols were approved by the Institutional Animal
Care and Use Committee. Standard Mouse Chow was used for all
experiments (Lab Diet #5001, 270 ppm iron). All mice had access
to food and water ad libitum.

Transferrin regimen
Mice were treated with 10 mg (400 mg/kg/day) of human apoTf
(Kamada, Israel) or same volume of PBS via intraperitoneal injections daily for 20 days. This course yielded results consistent with
previously published 60 days of injections13 (Online Supplementary
Figure S1A and B). Mice were sacrificed on day 3 after the last injection and samples processed for analyses.

Serum parameter analyses
Mouse serum was separated and analyzed using ELISA kits for
hepcidin (Hepcidin-Murine CompeteTM competitive ELISA,
Intrinsic LifeSciences, LLC, La Jolla, CA, USA), BMP2 (Abnova,
Taiwan), and the Integra 800 Automated Clinical Analyzer (Roche
Diagnostics, IN, USA) for other circulating iron-related parameters.

Non-heme iron spectrophotometry
Iron quantification was performed using the Torrance and
Bothwell method.29 Briefly, desiccated tissue samples were digested in acid-digestion mixture, diluted, and mixed with chromogen
reagent. Absorption was measured at 540 nm on a spectrophotometer (Multiskan MCC Microplate Reader, Fisher Scientific).

Primary culture of hepatocytes
Wild-type and thalassemic mouse livers were perfused with
PBS followed by Liberase TM (Roche Diagnostics, IN, USA) or filtered collagenase type 1 (Worthington, NJ, USA) using two-step
liver perfusion. Live cells were purified by Percoll (Sigma) and plathaematologica | 2016; 101(3)
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ed, as previously described.15 Cells were allowed to attach, starved
for 18 h, and treated for 24 h with 5% mouse serum with or without 20 mg/mL monoclonal anti-human BMP2/4 antibody (R&D
systems). Alternatively, WT serum-treated primary mouse hepatocytes were incubated with increasing doses of MEK/ERK1/2
inhibitor, U0126 [(freshly diluted in DMSO (Promega)] or DMSO
(Sigma) 2-2.5 h prior to cell harvest. Lastly, primary mouse hepatocytes were incubated with 5% FBS and increasing doses of
BMP2 (Sigma) for 24 h with and without U0126.

Western blot
Liver was homogenized with Protease and Phosphatase
Inhibitor Cocktail (Sigma) and total protein extracted. Freshly isolated or cultured hepatocytes were directly lysed by Cell Lysis
Buffer (Cell Signaling). Nuclear protein was prepared using NEPERTM Nuclear and Cytoplasmic Extraction Reagents (Thermo
Scientific) as per the manufacturer’s instructions. Briefly, samples
were homogenized, stained with 0.4% trypan blue, and analyzed
by western blot using sub-fraction specific controls. Specifically,
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Figure 1. Effect of apo-transferrin injection on ironrelated parameters. Serum iron (A) and transferrin
saturation (B) (measured in the serum as a ratio of
serum iron and total transferrin binding capacity) in
PBS-injected WT (n=8), PBS-injected thalassemic
(n=6), apoTf-treated WT (n=13), and apoTf-treated
thalassemic (n=6) mice. (C) Serum hepcidin concentration measured by ELISA in PBS-injected WT (n=24),
PBS-injected thalassemic (n=13), apo-transferrintreated WT (n=22), and apoTf-treated thalassemic
(n=14) mice. (D) Liver non-heme iron concentration
measured using spectrophotometry (n=12-14 mice
per group). (E) ERFE mRNA expression in sorted bone
marrow orthochromatophilic erythroblasts (n=4 sorted
samples per group, each sorted sample from 2-3
mice). Tf: transferrin; apo: apo-transferrin; WT: wild
type; thal: thalassemic (Hbbth1/th1); ERFE: erythroferrone.
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membranes were incubated with primary antibodies [Smad1,
pSmad1/5/8, Smad4, Ferritin H, ERK1/2, pERK1/2, and TBP
(TATA box binding protein) (Cell Signaling)]; Smad7 (Sigma);
TGIF, and Lamin B (Santa Cruz); GAPDH and β-actin (Thermo
Scientific); and BMP2 (Novus Biologicals)] as well as HRP-conjugated secondary antibodies (Thermo Scientific) and detected using
the SuperSignal West Dura Extended Duration Substrate (Thermo
Scientific). The results were quantified using Image J (v1.45q, NIH,
USA).

Immunofluorescence
Samples were fixed in 4% paraformaldehyde, washed, permeabilized, blocked, and incubated overnight with primary rabbit
anti-pSmad1/5/8 antibody. Control slides were incubated with
rabbit IgG. Slides were washed and stained with goat anti-rabbit

secondary antibody [(Alexa Fluor® 488 conjugate (Molecular
Probes)]. Coverslips were mounted and slides viewed using Zeiss
LSM 510 Meta Laser Scanning Confocal microscope.

Fluorescence-activated cell-sorting analysis
Bone marrow cells were processed and analyzed as described
previously.30 Briefly, cells were incubated with anti-CD45 magnetic beads and CD45 negative cells collected, counted, and incubated
with anti-mouse TER119-phycoerythrin-Cy7 (PE-Cy7) and CD44allophycocyanin (APC). Erythroid precursors were identified and
sorted using TER119, CD44, and forward scatter on MoFlo® XDP
High-Speed Cell Sorter (Beckman Coulter, Miami, FL, USA) using
Summit Software (Beckman Coulter, Miami, FL, USA). Post-sort
target population purity was confirmed by microscopic morphology evaluation of cytospins.
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Figure 2. Effect of apo-transferrin treatment
on Smad and ERK1/2 signaling to hepcidin in
hepatocytes. (A) Phosphorylated Smad1/5/8,
Smad1, Smad4, and Smad7, phosphorylated
ERK1/2, total ERK1/2, and Ferritin H in fresh
hepatocytes detected by western blot (representative gel; n = 6-7 mice per group). (B)
Statistical analysis of phosphorylated
Smad1/5/8:total Smad1:GAPDH in fresh
hepatocytes performed using ImageJ, presented as mean ± SEM (n = 6-7 mice per group).
(C) Statistical analysis of phosphorylated
ERK1/2:total ERK1/2 relative to GAPDH in
fresh hepatocytes performed using ImageJ,
presented as mean ± SEM (n=6-7 mice per
group). apo: apo-transferrin; WT: wild type; thal:
thalassemic (Hbbth1/th1).
haematologica | 2016; 101(3)
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RNA extraction and quantitative real-time RT-PCR
RNA from hepatocytes or livers was purified using PureLink
RNA Mini Kit (Ambion, Life Technology) and analyzed with
SuperScript III Platinum SYBR Green One-Step qRT-PCR Kit
(Invitrogen, Life Technology). Hepcidin and ERFE mRNA was
detected, as previously reported.12 Primers for mouse BMP6 were
designed and confirmed (Online Supplementary Table S1). We normalized mRNA concentrations to GAPDH.8

Statistical analysis
All data are reported as mean±standard error (SEM). Analysis
for statistically significant differences was performed using
Student’s unpaired t-test.

Results
Increased hepcidin and improved iron-related
parameters in apoTf-treated thalassemic mice
To evaluate apoTf's effect on iron metabolism, we meas-

ured circulating and cellular iron-related parameters in WT,
thalassemic, and apoTf-treated WT and thalassemic mice.
Serum iron concentration is higher in thalassemic compared
to WT mice, and significantly decreases in apoTf-treated
mice (Figure 1A). As previously demonstrated,13 WT and
thalassemic mice exhibit similar transferrin saturations
which significantly decrease in apoTf-treated mice (Figure
1B and Online Supplementary Figure S1B). Serum hepcidin
concentration (Figure 1C) and liver Hamp1 mRNA expression (Online Supplementary Figure S2A) exhibit similar patterns; although no difference in hepcidin is observed
between WT and thalassemic mice, apoTf increases hepcidin expression (Figure 1C and Online Supplementary Figure
S2A). Furthermore, Id1 mRNA expression is significantly
increased in apoTf-treated thalassemic mice (Online
Supplementary Figure S2A). No differences are observed in
other genes relevant to hepcidin regulation (e.g. Tfr2, HFE,
HJV, and Tfr1) either between WT and thalassemic mice or
between PBS-injected and apoTf-treated thalassemic mice
(Online Supplementary Figure S2B and C).
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Figure 3. Effect of apo-transferrin injection
on nuclear Smad signaling in hepatocytes.
(A) Phosphorylated Smad1/5/8, Smad4,
Smad7, and TGIF in hepatocyte nuclei detected by western blot (representative gel; n=4-6
mice per group in each experiment).
Statistical analysis of phosphorylated
Smad1/5/8 (B) and Smad 4 (C) relative to
Lamin B (lower band) in hepatocyte nuclei
performed using ImageJ, presented as mean
± SEM (n=4-6 mice per group). apo: apotransferrin; WT: wild type; thal: thalassemic
(Hbbth1/th1).
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Hepcidin concentration is similar in WT and thalassemic
mice despite increased liver iron concentration in thalassemic mice (Figure 1D). Importantly, increased hepcidin
in apoTf-treated thalassemic mice occurs despite
decreased liver iron concentration (Figure 1D), consistent
with previously published work on thalassemic mice.13
ApoTf injections increase hepcidin expression relative to
liver iron in both WT and thalassemic mice (Online
Supplementary Figure S2D). These findings led us to evaluate known iron-responsive regulators of hepcidin expression, including the BMP/SMAD pathway.

Nuclear pSmad1/5/8 and Smad4 increased in
apoTf-treated thalassemic hepatocytes
No changes in pSmad1/5/8:Smad1:GAPDH are
observed between freshly isolated primary hepatocytes
from WT, thalassemic, and apoTf-treated mice (Figure 2A
and B). Although thalassemic mice exhibit a greater iron
concentration, both in the liver (Figure 1D) and in isolated
hepatocytes (Figure 2A), pSmad1/5/8:Smad1:Ferritin H is
reduced compared to WT mice and increased by apoTf
treatment (Online Supplementary Figure S2E). This finding
suggests that exogenous apoTf partially restores Smad
pathway responsiveness to hepatocellular iron stores and
that activation of Smad1/5/8 is inappropriately low in thalassemic mice, consistent with previous findings.5 No dif-

ference in total cellular Smad4 is observed (Figure 2A).
To further assess the Smad pathway, we analyzed positive (Smad 1/5/8 and Smad 4) and negative (TGIF and
Smad7) regulatory Smads in hepatocyte nuclear fractions.31,32 Nuclear pSmad1/5/8 and Smad4 are suppressed
in thalassemic mice and increased in apoTf-treated thalassemic mice (Figure 3A-C). Increased hepcidin mRNA
expression in apoTf-treated thalassemic mice occurs
despite increased Smad7 mRNA expression (Online
Supplementary Figure S2A) and independent of Smad7 protein concentration as no changes are observed in either
total cellular or nuclear fractions (Figures 2A and 3A). TGIF
remains unchanged in hepatocyte nuclear fractions from
WT, thalassemic, and apoTf-treated thalassemic mice
(Figure 3A). Taken together, these findings demonstrate
that hepatocellular nuclear pSmad1/5/8 and Smad4
increase in apoTf-treated thalassemic mice despite
decreased circulating and tissue iron concentrations.

MEK/ERK1/2 pathway inhibition in vivo and in vitro
correlates with increased hepcidin expression
Because MEK/ERK1/2 signaling has been proposed in
hepcidin regulation, we investigate pERK1/2 in primary
mouse
hepatocytes.
Both
pERK1/2
and
pERK1/2:ERK1/2:GAPDH are increased in freshly isolated
hepatocytes from thalassemic mice (Figure 2A and C).
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Figure 4. Effects of MEK/ERK1/2 inhibitor
U0126 on hepcidin expression in vitro.
Hepcidin mRNA expression (A) as well as cellular ERK1/2 and Smad1/5/8 signaling (B
and C) in primary hepatocytes from WT and
thalassemic mice. Cells were cultured with
WT mouse serum in the presence of 0, 2, 10,
or 50 mM U0126 added 2.5 h prior to cell
harvest, normalized to DMSO treated control
cells. (D) Nuclear pSmad1/5/8 and Smad4
in WT primary hepatocytes treated with escalating doses of U0126 as above. These in
vitro results represent 3-6 independent
experiments. WT: wild type; TBP: TATA box
binding protein.
haematologica | 2016; 101(3)
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Both pERK1/2 and pERK1/2:ERK1/2:GAPDH are
decreased in apoTf-treated mice (Figure 2A and C), suggesting that increased hepcidin in apoTf-treated mice is a
consequence of ERK1/2 pathway suppression. No changes
in MEK/ERK1/2 signaling were observed using liver tissue
(data not shown), consistent with prior results in iron-overloaded mice.33
To confirm that ERK1/2 signaling inhibits hepcidin
expression, we evaluated serum-treated primary WT and
thalassemic hepatocytes and demonstrate a dose-depen-

A

dent decrease in pERK1/2 and increase in hepcidin
expression in response to MEK/ERK1/2 inhibitor, U0126
(Figure 4A-C). U0126 treatment did not change total cellular pSmad1/5/8 (Figure 4B), but nuclear pSmad1/5/8
increased in U0126-treated hepatocytes (Figure 4D), suggesting that increased hepcidin expression in apoTftreated mice is related to decreased hepatocellular
pERK1/2 (Figure 1C and Online Supplementary Figure S2A)
and functions through increased nuclear pSmad1/5/8 and
Smad4.
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Figure 5. Effect of apo-transferrin treatment on hepcidin regulators BMP2 and BMP6. (A) Liver BMP6 mRNA expression measured by q-RT PCR
relative to GAPDH mRNA and normalized to PBS-injected WT mice (n=8-12 mice per group). (B) Statistical analysis of BMP6 mRNA relative to
non-heme liver iron, presented as mean ± SEM (n=8-12 mice per group). (C) Serum BMP2 concentration measured by ELISA (n=6-9 mice per
group). Western blot (D, representative gel) and statistical analysis (E) of liver BMP2 protein concentration (n=6-9 mice per group).
apo: apo-transferrin; WT: wild type; thal: thalassemic (Hbbth1/th1).
haematologica | 2016; 101(3)
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Figure 6. Effects of mouse serum,
MEK/ERK1/2 inhibitor U0126, BMP2,
and neutralizing BMP2/4 antibody on
hepcidin expression in vitro. Hepcidin
mRNA expression (A) and Smad and
ERK1/2 pathway activation (B) in primary
WT hepatocytes cultured with different
mice sera, with and without the addition
of neutralizing anti-BMP2/4 antibodies,
and compared with primary cultured
hepatocytes directly treated with apotransferrin. Results are normalized to
untreated hepatocytes in culture.
Concurrent treatment with serum and
neutralizing anti-BMP2/4 antibodies compared with serum or anti-BMP2/4 antibody alone (*P<0.05 and **P<0.004 for
each paired condition with and without
added anti-BMP2/4 antibody). Gray: no
serum. (C) Quantification of phosphorylated relative to total Smad in primary WT
hepatocytes treated with WT or thalassemic mouse serum. Hepcidin mRNA
(D) as well as ERK1/2 and Smad1/5/8
signaling (E) in WT primary hepatocytes
treated with 20 ng/mL BMP2, 25 mM
U0126, or the combination. These in vitro
results represent 6 independent experiments. (F) Nuclear pSmad1/5/8 and
Smad4 in WT primary hepatocytes treated
with 20 ng/mL BMP2, 25 mM U0126, or
the combination as above. These in vitro
results represent 2 independent experiments. (G) Immunofluorescence using
anti-pSmad1/5/8 antibodies in WT primary hepatocytes treated with 20 ng/mL
BMP2, 25 mM U0126, or the combination
as above. (H) Results were quantified
using mean nuclear fluorescence intensity
in ImageJ. These in vitro results represent
4 independent experiments. UT: untreated; apo: apo-transferrin; WT: wild-type;
thal: thalassemic (Hbbth1/th1); RPL4: ribosomal protein L4; TBP: TATA box binding protein.
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thal

Hepcidin

BMP2 is associated with increased hepcidin expression
in apoTf-treated thalassemic mice
Because BMPs regulate hepcidin via Smad signaling, we
investigated BMPs in PBS-injected and apoTf-treated
mice. We utilized whole liver samples for Bmp6 mRNA
analysis, in the light of evidence that BMP6 induction by
dietary iron occurs primarily in liver non-parenchymal
cells, rather than hepatocytes.34 In agreement with this,
hepatocytes exposed in vitro to mouse serum exhibit
unchanged Bmp6 expression (data not shown). Although
liver Bmp6 expression is significantly increased in thalassemic mice (Figure 5A), consistent with higher nonheme liver iron in these mice (Figure 1D), serum hepcidin
and liver hepcidin mRNA expression are unchanged from
WT mice (Figure 1B and Online Supplementary Figure S2A).
Liver Bmp6 expression relative to iron concentration is also
suppressed in thalassemic mice (Figure 5B).
However, no significant change in Bmp6 expression
[either absolute (Figure 5A) or relative to liver iron (Figure
5B)] is observed in apoTf-treated thalassemic mice despite
a decrease in liver iron (Figure 1D) and increased Bmp6
expression in apoTf-treated WT mice (Figure 5A and B).
We, therefore, evaluated the potential role of other BMPs
in hepcidin regulation in apoTf-treated thalassemic mice.
Serum and liver BMP2 concentration are lower in thalassemic mice and increased in apoTf-treated thalassemic
mice (Figure 5C-E); BMP2 is also increased in apoTf-treated WT mice (Figure 5D and E). BMP2 mRNA and protein
expression are undetectable in sorted bone marrow erythroid precursors (data not shown), and BMP2 expression in
hepatocytes is lower relative to liver with no difference
between PBS-injected and apoTf-treated WT and thahaematologica | 2016; 101(3)

thal-apo

Hepcidin

Figure 7. Proposed working model of hepcidin regulation in apo-transferrin-treated
thalassemic mice. Apo-transferrin treatment induces circulating BMP2, decreases circulating ERFE, and decreases activation of ERK1/2 in hepatocytes, resulting
in increased nuclear Smad signaling and
hepcidin expression. ERFE: erythroferrone; thal: thalassemic (Hbbth1/th1); apo:
apo-transferrin.

lassemic mice (Online Supplementary Figure S3). No differences in serum BMP4 concentration (Online Supplementary
Figure S4A) or mRNA expression in the liver or hepatocytes (Online Supplementary Figure S2B and C) are
observed, and liver as well as bone marrow BMP4 are
undetectable by western blot (data not shown). These findings suggest that like BMP6, non-parenchymal cells are the
main source of BMP2 in the liver, correlating with the
increased hepcidin expression in apoTf-treated mice.
To further evaluate the role of BMP2 in apoTf-mediated
hepcidin regulation, we analyzed the effect of neutralizing
anti-BMP2/4 antibody on serum-treated cultured primary
WT hepatocytes. To test the validity of this in vitro
method, we demonstrate suppressed hepcidin expression
and pSmad1/5/8 (Figure 6A-C) with unchanged Smad4
and Smad7 concentrations (data not shown) in hepatocytes
treated with serum from thalassemic relative to WT mice,
providing evidence of a robust culture system.35 Hepcidin
expression is also increased in serum-treated relative to
untreated cells (Figure 6A). No differences are observed in
apoTf-treated relative to untreated hepatocytes or those
treated with serum from apoTf- relative to PBS-treated
mice (Figure 6A and B), providing evidence of nonparenchymal cell involvement via BMP2 and BMP6 on
hepcidin expression. Primary hepatocytes concurrently
treated with serum and neutralizing anti-BMP2/4 antibody exhibit suppressed hepcidin expression in each condition relative to serum alone conditions (Figure 6A), again
suggesting the importance of extra-cellular BMP2 in hepcidin regulation. A similar pattern of pSmad1/5/8 mRNA
and protein suppression is seen in cells exposed to serum
with and without anti-BMP2/4 antibody (Figure 6A-C). As
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expected, Id1 mRNA expression mimics changes in hepcidin expression (Online Supplementary Figure S5).
Surprisingly, MEK/ERK1/2 pathway activation is
increased in hepatocytes treated by the neutralizing antibody (Figure 6B), suggesting that BMP2 is involved in hepcidin regulation via the MEK/ERK1/2 pathway.
To further explore the relationships between BMP-Smad
and MEK/ERK1/2 pathways, mouse primary hepatocytes
were treated with different doses of BMP2 and U0126. In
response to BMP2, we observe dose-dependent increases
in hepcidin expression and pSmad1/5/8; and decrease in
MEK/ERK1/2 (Online Supplementary Figure S6A and B).
When primary hepatocytes are treated with BMP2 (20
ng/mL), U0126 (25 mM) or the combination, BMP2 and
U0126 each induce hepcidin expression with an additive
combined effect (Figure 6D). During these treatments, the
ERK1/2 pathway is effectively suppressed by U0126 and
by BMP2. Total cellular pSmad1/5/8 is minimally affected
by the addition of BMP2 or U0126 individually but
induced with the combination of BMP2 and U0126 (Figure
6E). However, BMP2, U0126, and their combination
induce nuclear pSmad1/5/8 and especially Smad4 by
western blot (Figure 6F) and immunofluorescence (Figure
6G and H). These findings demonstrate that BMP2 signaling and MEK/ERK1/2 suppression each up-regulate hepcidin by increasing nuclear pSMAD1/5/8 and especially
Smad4 concentrations in an additive way.

ApoTf-induced hepcidin increase correlates with ERFE
suppression only in thalassemic mice
We evaluated candidate “erythroid regulators” in apoTftreated thalassemic mice. No differences were observed in
GDF15 (data not shown), TWSG1 (Online Supplementary
Figure S7), or GDF11 (Online Supplementary Figure S7)
between bone marrow erythroblasts from WT, thalassemic, and apoTf-treated mice. However, ERFE expression is increased in bone marrow erythroblasts in thalassemic mice and normalized in apoTf-treated thalassemic mice but is surprisingly increased in apoTf-treated WT mice (Figure 1E). These findings support the importance of ERFE as an erythroid regulator in thalassemic
mice, suggest that the effect in th1/th1 mice and th3/+
mice12 is comparable, and provide data consistent with our
previously published evidence that apoTf treatment
reverses ineffective erythropoiesis in thalassemic mice.13
Similar results have recently been reported in apoTf-treated th3/+ mice.36 Lastly, increased hepcidin expression in
apoTf-treated WT mice occurs despite an increase in
ERFE, suggesting that increased liver BMP2 in apoTf-treated WT and thalassemic mice functions, at least in part,
through suppression of MEK/ERK1/2 pathway.

Discussion
Thalassemia provides a model system for investigating
the dual and competitive regulation of hepcidin by iron
and erythropoiesis. Based on prior observations, we proposed that exogenous apoTf provides a window into the
mechanisms responsible for this dual regulation. We
found that in apoTf-treated thalassemic mice, hepcidin
expression is increased despite a decrease in circulating
and parenchymal iron; ERFE expression is decreased in the
bone marrow, likely responsible for hepcidin de-repression; increased BMP2 but not BMP6 expression are also
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involved; and MEK/ERK1/2 pathway activation inversely
correlates with hepcidin expression.
As previously reported,13 apoTf-treated mice did not
exhibit any toxicity in our experiments, and exogenous
apoTf’s effect on iron and erythropoiesis is similar
whether administered to older (9-10 months)13 or younger
(8-10 weeks) mice. Furthermore, 20 days of daily apoTf
injections result in effects similar (Online Supplementary
Table S2) to 60 days of injections (Online Supplementary
Figure S1A and B). ApoTf-treated thalassemic mice exhibit
a decrease in systemic iron overload. In addition, hepcidin
mRNA expression is again unchanged in thalassemic relative to WT mice and increased in apoTf-treated thalassemic mice.13 A mouse serum hepcidin ELISA has
recently been developed37 and demonstrates a strong correlation with hepcidin mRNA. Increased hepcidin expression in apoTf-treated thalassemic mice occurs despite
decreased serum or liver iron, cytosolic Ferritin H, and circulating transferrin saturation, as previously reported,13
and thus does not reflect changes in iron status.
Although BMP6 is important in hepcidin regulation, we
previously demonstrated that Bmp6 expression is insufficiently increased relative to liver iron in th3/+ mice.5 Our
current data further demonstrate that liver Bmp6 mRNA
expression is unchanged in apoTf-treated thalassemic
mice. Furthermore, Bmp6 is suppressed relative to liver
iron, and although total pSmad1/5/8 is unchanged, nuclear
pSmad1/5/8 and Smad4 are suppressed in thalassemic
mice, together suggesting that BMP receptor stimulation is
dampened and unable to increase nuclear pSmad despite
increased Bmp6 expression. Similar findings have been
demonstrated in th3/+ mice.38 Lastly, because liver Bmp6
mRNA expression is increased in apoTf--treated WT but
not thalassemic mice, we hypothesize that BMP6 is
involved in hepcidin regulation in response to more acute
changes in iron status and not to chronic iron overload in
thalassemic mice.
Because other BMPs are involved in Smad1/5/8 activation and hepcidin expression in vitro,15 we explored the role
of BMP2 in hepcidin regulation of apoTf-treated thalassemic mice. Our results demonstrate that BMP2 is
decreased in the sera and livers of thalassemic mice and
increased in sera and livers from apoTf-treated thalassemic mice. These findings are consistent with previously published work on BMP2 expression in human liver
tissue and hepatoma-derived cell lines,20 and nonparenchymal cells in the rat liver.39 We hypothesize that
increased hepcidin in apoTf-treated mice is at least in part
due to liver-secreted BMP2 because: 1) BMP2 protein is
not detectable in hepatocytes, suggesting that nonparenchymal cells in the liver are involved; 2) nonparenchymal cells in the liver are of mesenchymal origin,
the same cells previously implicated in BMP6 secretion;34
3) BMP2 secretion has been demonstrated from cells of
mesenchymal origin (e.g. vascular and skeletal cells).40,41
Taken together, these data strongly suggest that nonparenchymal cells of the liver and other organs secrete
BMP2 to enable paracrine and endocrine effects on hepcidin regulation in the liver.
A previous publication showed that exogenous BMP2
increases hepcidin expression and lowers serum-iron levels in mice14 and that BMP inhibitor, noggin, as well as
neutralizing anti-BMP2/4 antibodies block hepcidin
response to serum and transferrin.21 The increased BMP2
in human sera activates hepcidin expression in vitro, is
haematologica | 2016; 101(3)
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blocked by BMP2 immunodepletion,42 and hepcidin suppression correlates with BMP2 suppression in mice.43 This
previous publication supports the role of BMP2 in apoTfinduced hepcidin upregulation. To further evaluate the
effect of BMP2 on hepcidin expression, we treated primary hepatocytes with mouse serum and neutralizing
BMP2/4 antibody. Although neutralizing anti-BMP2/4
antibodies suppress hepcidin expression and pSmad1/5/8
as expected, pERK1/2 is increased in neutralizing antiBMP2/4 antibody-treated hepatocytes relative to serum
alone. These findings further support our finding that
MEK/ERK1/2 signaling is increased in thalassemic mice
and suppressed in apoTf-treated mice.
Transferrin in primary hepatocyte cultures demonstrates complex changes in MEK/ERK1/2 signaling and
relationship to Smad signaling. In vitro, transient induction
of MEK/ERK1/2, Smad1/5/8, and hepcidin expression are
observed in serum and/or transferrin-treated primary WT
mouse hepatocytes, all blocked by U0126.21 In vivo, neither
acute nor chronic iron induced increases in liver pERK1/2
in WT mice,4 despite associated changes in hepcidin
expression. Taken together, these reported observations
leave considerable uncertainty regarding the relationship
between transferrin, pERK1/2, and hepcidin expression.
We demonstrate for the first time increased pERK1/2 in
hepatocytes from thalassemic relative to WT mice and
decreased pERK1/2 in apoTf-treated thalassemic mice.
Hepatocellular pERK1/2 is inversely correlated with hepcidin expression and nuclear Smad in thalassemic mice. In
primary hepatocytes, U0126 results in the expected doseresponse inhibition of MEK/ERK1/2 and increased hepcidin expression. These in vitro experiments reveal, despite
unchanged cellular or cytosolic pSmad1/5/8, increased
nuclear pSmad1/5/8 and Smad4 when MEK/ERK1/2 is
suppressed. In addition, BMP2- and U0126-treated primary mouse hepatocytes reveal an additive increase in
hepcidin expression relative to treatment with either agent
alone, suggesting a cross-acting function between BMP2Smad1/5/8 and MEK/ERK1/2 pathways. Supporting these
observations, a screen using small-molecule kinase
inhibitors found that MEK/ERK1/2 pathway inhibitors
increase hepcidin in primary hepatocytes44 and
MEK/ERK1/2 activators decrease BMP-dependent nuclear
Smad.28,44,45 Taken together, our data suggest that activation of hepatocyte MEK/ERK1/2 pathway inhibits hepcidin expression by decreasing nuclear Smad, and that
these effects are attenuated by treatment with apoTf.
In thalassemic mice, exogenous apoTf reverses ineffective erythropoiesis and increases hepcidin expression13
likely by reducing circulating “erythroid regulator” suppression of hepcidin. Prior reports demonstrated that
GDF15 does not play a role in erythroid regulation of hepcidin in mice.38,46 We also analyzed TWSG1 and GDF11
mRNA and did not observe any differences in erythroid
precursors between PBS- and apoTf-treated thalassemic
mice. However, ERFE mRNA expression is increased in
thalassemic mice and normalized in apoTf-treated tha-

References
1. Nemeth E. Hepcidin in β-thalassemia. Ann
Ny Acad Sci. 2010;1202(1):31-35.
2. Nemeth E, Tuttle MS, Powelson J, et al.

haematologica | 2016; 101(3)

lassemic mice. Because ERFE expression is dependent on
STAT5 signaling via erythropoietin receptor,12 decreased
ERFE expression in apoTf-treated thalassemic mice is likely a consequence of improved erythroid maturation and
RBC survival, leading to a decrease in serum erythropoietin and reversal of splenomegaly.13 This finding confirms
the importance of ERFE and its role in the reversal of ineffective erythropoiesis in apoTf-treated thalassemic mice.
Furthermore, ERFE expression is increased in apoTf-treated WT mice, consistent with increased erythropoietin13
and reticulocyte counts (Online Supplementary Table S2).
Thus, hepcidin expression in apoTf-treated WT mice is
increased despite increased ERFE, suggesting that BMP2
provides a dominant effect to increase hepcidin expression
and that increased hepcidin expression in apoTf-treated
thalassemic mice is a combined effect of increased BMP2
and decreased ERFE. Reagents are currently under development to elucidate ERFE regulation of hepcidin in apoTftreated thalassemic mice.
We hypothesize that liver and/or serum BMP2 is a previously unexplored upstream suppressor of the
MEK/ERK1/2 pathway, inducing hepcidin expression
(Figure 7). The mechanism by which this occurs is not yet
clear. One possibility is that changes in BMP binding
endothelial cell precursor-derived regulator (BMPER)
affects BMP signaling. Indeed, the concept of BMPER regulation of hepcidin via BMP2 has recently been published.47 Smad-independent signaling for TGFβ family of
ligands, including BMPs, has been proposed.22 BMP2 exerts
its function through both MEK/ERK1/2 and Smad pathways in primary cultured osteoblasts48,49 and it has been
proposed that cells of mesenchymal origin exhibit
enhancement while cells of epithelial origin exhibit inhibition of Smad signaling by the MEK/ERK1/2 pathway.25
The details of a potentially significant cell autonomous
cross-talk between the MEK/ERK1/2 and BMP/Smad
pathways remain to be elucidated.
Further studies are necessary to explore the potential use
of exogenous apoTf to reverse ineffective erythropoiesis
in β-thalassemia and other diseases of concurrent anemia
and iron overload. Our data present mechanisms for hepcidin de-repression in apoTf-treated thalassemic mice,
provide additional therapeutic targets in this pathway, and
support our hypothesis that reversal of ineffective erythropoiesis and iron overload require concurrent management
in β-thalassemia.
Funding
This work was supported by NHLBI (to YZG; HL105682),
NIDDK (to YZG, SR, REF; DK095112), and New York Blood
Center funding to the Erythropoiesis Laboratory.
Acknowledgments
We extend special thanks to the Jacobi Medical Center for
sample analysis, E. Nemeth, M. Socolovsky, and P. Ney for stimulating discussions, and T. Ganz and M. Narla for unparalleled
guidance and support.

Hepcidin regulates cellular iron efflux by
binding to ferroportin and inducing its
internalization.
Science.
2004;306(5704):2090-2093.
3. Kautz L, Meynard D, Monnier A, et al. Iron
regulates phosphorylation of Smad1/5/8

and gene expression of Bmp6, Smad7, Id1,
and Atoh8 in the mouse liver. Blood.
2008;112(4):1503-1509.
4. Corradini E, Rozier M, Meynard D, et al.
Iron regulation of hepcidin despite attenuated Smad1,5,8 signaling in mice without

307

H. Chen et al.
transferrin
receptor
2
or
Hfe.
Gastroenterology. 2011;141(5):1907-1914.
5. Parrow NL, Gardenghi S, Ramos P, et al.
Decreased hepcidin expression in murine
beta-thalassemia is associated with suppression of Bmp/Smad signaling. Blood.
2012;119(13):3187-3189.
6. De Franceschi L, Daraio F, Filippini A, et al.
Liver expression of hepcidin and other iron
genes in two mouse models of beta-thalassemia. Haematologica. 2006;91(10):
1336-1342.
7. Gardenghi S, Marongiu MF, Ramos P, et al.
Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron
absorption mediated by down-regulation
of hepcidin and up-regulation of ferroportin. Blood. 2007;109(11):5027-5035.
8. Vokurka M, Krijt J, Sulc K, Necas E.
Hepcidin mRNA levels in mouse liver
respond to inhibition of erythropoiesis.
Physiol Res. 2006;55(6):667-674.
9. Tanno T, Bhanu NV, Oneal PA, et al. High
levels of GDF15 in thalassemia suppress
expression of the iron regulatory protein
hepcidin. Nat Med. 2007;13(9):1096-1101.
10. Tanno T, Porayette P, Sripichai O, et al.
Identification of TWSG1 as a second novel
erythroid regulator of hepcidin expression
in murine and human cells. Blood.
2009;114(1):181-186.
11. Dussiot M, Maciel TT, Fricot A, et al. An
activin receptor IIA ligand trap corrects
ineffective erythropoiesis in beta-thalassemia. Nat Med. 2014;20(4):398-407.
12. Kautz L, Jung G, Valore EV, Rivella S,
Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of
iron metabolism. Nat Genet. 2014;46(7):
678-684.
13. Li H, Rybicki AC, Suzuka SM, et al.
Transferrin therapy ameliorates disease in
beta-thalassemic
mice.
Nat
Med.
2010;16(2):177-182.
14. Babitt JL, Huang FW, Xia Y, Sidis Y,
Andrews NC, Lin HY. Modulation of bone
morphogenetic protein signaling in vivo
regulates systemic iron balance. J Clin
Invest. 2007;117(7):1933-1939.
15. Lin L, Valore EV, Nemeth E, Goodnough JB,
Gabayan V, Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and
BMP2/4. Blood. 2007;110(6):2182-2189.
16. Hentze MW, Muckenthaler MU, Galy B,
Camaschella C. Two to tango: regulation of
Mammalian iron metabolism. Cell.
2010;142(1):24-38.
17. Andriopoulos BJ, Corradini E, Xia Y, et al.
BMP6 is a key endogenous regulator of
hepcidin expression and iron metabolism.
Nat Genet. 2009;41(4):482-487.
18. Meynard D, Kautz L, Darnaud V, CanonneHergaux F, Coppin H, Roth MP. Lack of the
bone morphogenetic protein BMP6 induces
massive iron overload. Nat Genet.
2009;41(4):478-481.
19. Ramos E, Kautz L, Rodriguez R, et al.
Evidence for distinct pathways of hepcidin
regulation by acute and chronic iron loading in mice. Hepatology. 2011;53(4):13331341.
20. Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY.
Hemojuvelin regulates hepcidin expression
via a selective subset of BMP ligands and
receptors independently of neogenin.

308

Blood. 2008;111(10):5195-5204.
21. Ramey G, Deschemin JC, Vaulont S. Crosstalk between the mitogen activated protein
kinase
and
bone
morphogenetic
protein/hemojuvelin pathways is required
for the induction of hepcidin by holotransferrin in primary mouse hepatocytes.
Haematologica. 2009;94(6):765-772.
22. Derynck R, Zhang YE. Smad-dependent
and Smad-independent pathways in TGFbeta family signalling. Nature. 2003;425
(6958):577-584.
23. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling
downstream of TGF-beta: implications for
carcinogenesis. Oncogene. 2005; 24(37):
5742-5750.
24. Lutz M, Knaus P. Integration of the TGFbeta pathway into the cellular signalling
network. Cell Signal. 2002;14(12):977-988.
25. Hayashida T, Decaestecker M, Schnaper HW.
Cross-talk between ERK MAP kinase and
Smad signaling pathways enhances TGFbeta-dependent responses in human mesangial cells. FASEB J. 2003;17(11):1576-1578.
26. Kretzschmar M, Doody J, Timokhina I,
Massague J. A mechanism of repression of
TGFbeta/ Smad signaling by oncogenic
Ras. Genes Dev. 1999;13(7):804-816.
27. Calzolari A, Raggi C, Deaglio S, et al. TfR2
localizes in lipid raft domains and is
released in exosomes to activate signal
transduction along the MAPK pathway. J
Cell Sci. 2006;119(Pt 21):4486-4498.
28. Poli M, Luscieti S, Gandini V, et al.
Transferrin receptor 2 and HFE regulate
furin expression via mitogen-activated protein kinase/extracellular signal-regulated
kinase (MAPK/Erk) signaling. Implications
for transferrin-dependent hepcidin regulation. Haematologica. 2010;95(11):18321840.
29. Torrance JD, Bothwell TH. Tissue iron
stores. In: Cook JD eds. Iron-Methods in
hematology. New York, NY, USA:
Churchill Lingstone; 1980; Vol.1:90-115.
30. Liu J, Zhang J, Ginzburg Y, et al.
Quantitative analysis of murine terminal
erythroid differentiation in vivo: novel
method to study normal and disordered
erythropoiesis. Blood. 2013;121(8):e43-9.
31. Wotton D, Knoepfler PS, Laherty CD,
Eisenman RN, Massague J. The Smad transcriptional corepressor TGIF recruits
mSin3. Cell Growth Differ. 2001;12(9):457463.
32. Mleczko-Sanecka K, Casanovas G, Ragab
A, et al. SMAD7 controls iron metabolism
as a potent inhibitor of hepcidin expression. Blood. 2010;115(13):2657-2665.
33. Corradini E, Meynard D, Wu Q, et al.
Serum and liver iron differently regulate the
bone morphogenetic protein 6 (BMP6)SMAD signaling pathway in mice.
Hepatology. 2011;54(1):273-284.
34. Enns CA, Ahmed R, Wang J, et al. Increased
iron loading induces Bmp6 expression in
the non-parenchymal cells of the liver independent of the BMP-signaling pathway.
Plos One. 2013;8(4):e60534.
35. Weizer-Stern O, Adamsky K, Amariglio N,
et al. Downregulation of hepcidin and
haemojuvelin expression in the hepatocyte
cell-line HepG2 induced by thalassaemic
sera. Br J Haematol. 2006;135(1):129-138.

36. Gelderman MP, Baek JH, Yalamanoglu A, et
al. Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice. Haematologica.
2015;100(5):611-622.
37. Gutschow P, Schmidt PJ, Han H, et al. A
competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1:
correlation with hepatic mRNA expression
in established and novel models of dysregulated iron homeostasis. Haematologica.
2015;100(2):167-177.
38. Frazer DM, Wilkins SJ, Darshan D, Badrick
AC, McLaren GD, Anderson GJ. Stimulated
erythropoiesis with secondary iron loading
leads to a decrease in hepcidin despite an
increase in bone morphogenetic protein 6
expression. Br J Haematol. 2012;157(5):615626.
39. Zhang AS, Anderson SA, Wang J, et al.
Suppression of hepatic hepcidin expression
in response to acute iron deprivation is
associated with an increase of matriptase-2
protein. Blood. 2011;117(5):1687-1699.
40. Matsubara H, Hogan DE, Morgan EF,
Mortlock DP, Einhorn TA, Gerstenfeld LC.
Vascular tissues are a primary source of
BMP2 expression during bone formation
induced by distraction osteogenesis. Bone.
2012;51(1):168-180.
41. Martinovic S, Mazic S, Kisic V, et al.
Expression of bone morphogenetic proteins
in stromal cells from human bone marrow
long-term culture. J Histochem Cytochem.
2004;52(9):1159-1167.
42. Maes K, Nemeth E, Roodman GD, et al. In
anemia of multiple myeloma, hepcidin is
induced by increased bone morphogenetic
protein 2. Blood. 2010;116(18):3635-3644.
43. Liu S, Suragani RN, Han A, Zhao W,
Andrews NC, Chen JJ. Deficiency of hemeregulated eIF2alpha kinase decreases hepcidin expression and splenic iron in HFE-/mice. Haematologica. 2008;93(5):753-756.
44. Goodnough JB, Ramos E, Nemeth E, Ganz
T. Inhibition of hepcidin transcription by
growth factors. Hepatology. 2012;
56(1):291-299.
45. Kretzschmar M, Doody J, Massague J.
Opposing BMP and EGF signalling pathways converge on the TGF-beta family
mediator Smad1. Nature. 1997;389(6651):
618-622.
46. Casanovas G, Vujic SM, Casu C, et al. The
murine growth differentiation factor 15 is
not essential for systemic iron homeostasis
in phlebotomized mice. Haematologica.
2013;98(3):444-447.
47. Patel N, Masaratana P, Diaz-Castro J, et al.
BMPER protein is a negative regulator of
hepcidin and is up-regulated in hypotransferrinemic mice. J Biol Chem. 2012;
287(6):4099-4106.
48. Tang CH, Yang RS, Chien MY, Chen CC,
Fu WM. Enhancement of bone morphogenetic protein-2 expression and bone formation by coumarin derivatives via p38
and
ERK-dependent
pathway
in
osteoblasts. Eur J Pharmacol. 2008;579(13):40-49.
49. Su JL, Chiou J, Tang CH, et al. CYR61 regulates BMP-2-dependent osteoblast differentiation through the {alpha}v{beta}3 integrin/integrin-linked kinase/ERK pathway. J
Biol Chem. 2010;285(41):31325-31336.

haematologica | 2016; 101(3)

